# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...
The credit facility provides Precigen with up to $125 million committed across two tranches, subject to the terms and condition...
JMP Securities analyst Jason N. Butler maintains Precigen (NASDAQ:PGEN) with a Market Outperform and raises the price target...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:PGEN) with a Buy and maintains $8.5 price...